Monitor this situation.
Unsubscribe anytime.
[SITUATION] · [ACTIVE] · [BUSINESS]
2 clusters · 5 sources · 3 days · First seen · Last updated
Corporate financial performance reports
Overview
Recent reports indicate growth for various companies in different sectors. Atrys Health, a medical services provider, reported a 9.7% revenue increase to 117.1 million euros for the first nine months of 2026, driven by oncology and nuclear medicine segments. Allwyn, a lottery company, reported a 19% increase in net revenues to 1.22 billion euros for the third quarter of 2026, supported by product innovations and international availability.
Entities
PrizePicks · Atrys Health · Allwyn · Greece · United Kingdom
Claims
What the coverage asserts, and how many sources carry each claim.
- [● 2 SOURCES] Allwyn recorded net revenues of 1.22 billion euros in Q3 2026. www.capital.gr · marketnews.gr
- [● 2 SOURCES] Net revenues increased by 19% on a yearly basis. www.capital.gr · marketnews.gr
- [● 2 SOURCES] Adjusted EBITDA was 396 million euros. www.capital.gr · marketnews.gr
- [● 2 SOURCES] Adjusted EBITDA increased by 6% on a yearly basis. www.capital.gr · marketnews.gr
- [● 2 SOURCES] The company expects net revenue growth in the mid-to-high 20% range for 2026. www.capital.gr · marketnews.gr
- [● 2 SOURCES] Allwyn completed a 150 million euro share buyback program in October. www.capital.gr · marketnews.gr
- [● 2 SOURCES] An interim dividend of 0.20 euros per share was paid in November. www.capital.gr · marketnews.gr
- [● 2 SOURCES] Total distributions for the year amount to 1.00 euro per share. www.capital.gr · marketnews.gr
Timeline
-
[BUSINESS] 3 sourcesAllwyn reports 19% revenue growth in Q3 2026
Allwyn reported Q3 2026 net revenues of 1.22 billion euros, a 19% annual increase, and reaffirmed its 2026 growth outlook.
-
[BUSINESS] 2 sourcesAtrys Health reports 9.7% revenue growth in first nine months of 2026
Atrys Health reported a 9.7% revenue increase to 117.1 million euros and an 18.5% EBITDA rise during the first nine months of 2026, driven by oncology and nuclear medicine growth.
Sources
capital.gr · economiadigital.es · kosmoslarissa.gr · marketnews.gr · theofficer.es